摘要
目的利用AE亚型的膜蛋白,研发抗HI V-1 AE重组型的疫苗并进行免疫原性评价。方法构建表达中国流行株97CNGX2F(HI V-1 AE2F)包膜蛋白gp140的重组痘苗病毒rVVT140AE。使用表达gp140的DNA疫苗和rVVT140AE用初免-加强方式免疫小鼠。免疫结束后第2周处死小鼠,分别检测特异性抗体滴度和特异性T细胞反应。结果本疫苗所活化的特异性抗体滴度在3 200和51 200之间,几何平均值为11 143;总T细胞免疫反应强度为(1 918±442)SFCs/106脾细胞,其中针对env1、env2、env3、env4肽池的免疫反应强度分别为(1 280±330)SFCs/106脾细胞,(66±16)SFCs/106脾细胞,(163±34)SFCs/106脾细胞和(409±96)SFCs/106脾细胞,均显著高于空载体对照组(<10 SFCs/106脾细胞)。结论本实验构建的HI V-1 AE2F株包膜蛋白gp140重组痘苗病毒疫苗可作为针对我国HI V-1流行株的候选疫苗免疫原。
Objective To develop an HIV-1 AE recombinant envelope based vaccine since this recombinant has been accounted for high percent of sexual transmitted HIV-1 prevalence.Methods A recombinant Tiantan vaccinia based vaccines rVVT140AE expressing envelope gp140 from a circulating recombinant clade 97CNGX2F（HIV-1 AE2F） was constructed.DNA vaccine expressing gp140 and rVVT140AE was used to immunize mice with a prime/boost strategy.Mice were sacrificed 2 weeks after the final inoculation,then specific antibody titer and T cell responses were measured separately.Results The titers of env-specific antibodies elicited by this vaccines ranged from 3 200 to 51 200,with an geometric average at 11 143.Total T cell responses measured by ELISPOT was（1 918±442） SFCs/106 splenocytes with the responses against four peptide pools env1,env2,env3,env4 at（1 280±330） SFCs/10^6 splenocytes,（66±16） SFCs/10^6 splenocytes,（163±34） SFCs/10^6 splenocytes and（409±96） SFCs/10^6 splenocytes,which were all significantly higher than mock control group（〈10 SFCs/10^6 splenocytes）.Conclusions The HIV-1 AE2F envelope gp140 recombinant vaccinia virus vaccine can be used for HIV-1 strains candidate vaccine immunogen.
出处
《中华疾病控制杂志》
CAS
2010年第9期831-835,共5页
Chinese Journal of Disease Control & Prevention
基金
国家“十一五”重大科技专项课题(2008ZX10001-012)
国家自然科学基金(30771915)
关键词
HIV疫苗
包膜蛋白
疫苗
合成
HIV vaccine
Envelope protein
Vaccines
synthetic
